AKRO - AKRO Investor Notice: Abraham Fruchter & Twersky LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) | Benzinga
NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that focuses on protecting investors' rights, is investigating whether Akero Therapeutics (NASDAQ:AKRO), a clinical-stage biotechnology company, violated U.S. federal securities laws by making false or misleading statements or failing to timely disclose material information to investors.
According to a report by Investors Business Daily published on October 10, 2023, Akero's "liver-disease treatment fell short in a midstage ...
AKRO)>Full story available on Benzinga.com